BNTX BioNTech SE IFRS Annual reports only
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1776985 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 2.87B | 2.75B | 3.82B | 17.31B | 18.98B |
| Cost of revenue | 641.80M | 541.30M | 599.80M | 3.00B | 2.91B |
| Gross profit | 2.23B | 2.21B | 3.22B | 14.32B | 16.07B |
| R&D expense | 2.10B | 2.25B | 1.78B | 1.54B | 949.20M |
| SG&A expense | 514.40M | 531.10M | 495.00M | 481.70M | 276.80M |
| Operating income | -1.40B | -1.31B | 690.40M | 12.64B | 15.28B |
| Interest expense | 14.20M | 16.90M | 7.50M | 18.90M | 305.10M |
| Pretax income | -1.05B | -677.70M | 1.19B | 12.95B | 15.05B |
| Income tax | 85.30M | -12.40M | 255.80M | 3.52B | 4.75B |
| Net income | -1.14B | -665.30M | 930.30M | 9.43B | 10.29B |
| EBITDA | -1.02B | -1.02B | 873.80M | 12.77B | 15.36B |
| EPS (basic) | -4.70 | -2.77 | 3.87 | 38.78 | 42.18 |
| EPS (diluted) | -4.70 | -2.77 | 3.83 | 37.77 | 39.63 |
| Weighted avg. shares (diluted) | 241.70M | 240.40M | 242.70M | 249.80M | 259.70M |
| Balance sheet | |||||
| Cash & equivalents | 7.68B | 9.76B | 11.66B | 13.88B | 1.69B |
| Receivables | 924.20M | 1.46B | 2.16B | 7.15B | 12.38B |
| Inventory | 110.70M | 283.30M | 357.70M | 439.60M | 502.50M |
| Current assets | 16.15B | 18.80B | 19.53B | 21.92B | 15.07B |
| PP&E, netmay include right-of-use assets (IFRS) | 1.08B | 935.30M | 757.20M | 609.20M | 322.50M |
| Goodwill | 367.90M | 380.60M | 362.50M | 61.20M | 57.80M |
| Total assets | 21.99B | 22.53B | 23.01B | 23.28B | 15.83B |
| Current liabilities | 2.14B | 2.52B | 2.07B | 2.95B | 3.48B |
| Short-term debt | — | — | — | — | 129.90M |
| Long-term debt | — | — | — | — | 171.60M |
| Total debt | — | — | — | — | 301.50M |
| Total liabilities | 2.76B | 3.12B | 2.76B | 3.22B | 3.94B |
| Shareholders' equity | 19.22B | 19.41B | 20.25B | 20.06B | 11.89B |
| Net debt | — | — | — | — | -1.39B |
| Shares outstanding | 251.33M | 239.97M | 237.73M | 243.22M | 242.52M |
| Cash flow statement | |||||
| Operating cash flow | 456.00M | 207.70M | 5.37B | 13.58B | 889.70M |
| Capital expenditure | 175.10M | 286.50M | 249.40M | 329.20M | 127.50M |
| Free cash flow | 280.90M | -78.80M | 5.12B | 13.25B | 762.20M |
| Investing cash flow | -2.47B | -2.08B | -6.95B | -35.30M | -566.10M |
| Financing cash flow | -52.90M | -45.90M | -778.60M | -1.42B | 94.20M |
| Depreciation & amortization | 382.80M | 298.00M | 183.40M | 123.30M | 75.20M |
| Stock-based compensation | 106.20M | 100.90M | 51.40M | 108.60M | 93.90M |
| Dividends paid | — | 0 | 0 | 484.30M | 0 |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.